Michael D Hooven Net Worth

The estimated Net Worth of Michael D Hooven is at least 6.51 百万$ dollars as of 5 May 2017. Michael Hooven owns over 10,000 units of Atricure Inc stock worth over 1,803,618$ and over the last 19 years Michael sold ATRC stock worth over 4,705,059$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Hooven ATRC stock SEC Form 4 insiders trading

Michael has made over 15 trades of the Atricure Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Michael exercised 10,000 units of ATRC stock worth 95,000$ on 5 May 2017.

The largest trade Michael's ever made was selling 142,268 units of Atricure Inc stock on 30 March 2015 worth over 2,960,597$. On average, Michael trades about 12,319 units every 134 days since 2005. As of 5 May 2017 Michael still owns at least 67,049 units of Atricure Inc stock.

You can see the complete history of Michael Hooven stock trades at the bottom of the page.

What's Michael Hooven's mailing address?

Michael's mailing address filed with the SEC is 6033 SCHUMACHER PARK DRIVE, , WEST CHESTER, OH, 45069.

Insiders trading at Atricure Inc

Over the last 19 years, insiders at Atricure Inc have traded over 52,789,242$ worth of Atricure Inc stock and bought 666,621 units worth 5,937,195$ . The most active insiders traders include Scott William Drake、Group I, Llc Donoghue Danie...、Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of 548,410$. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth 84,245$.

What does Atricure Inc do?

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.

Complete history of Michael Hooven stock trades at Atricure Inc

Atricure Inc executives and stock owners

Atricure Inc executives and other stock owners filed with the SEC include:

• Michael Carrel,
  President, Chief Executive Officer, Director
• Douglas Seith,
  Chief Operating Officer
• Salvatore Privitera,
  Chief Technology Officer
• Justin Noznesky,
  Senior Vice President, Marketing and Business Development
• Scott Drake,
  Independent Chairman of the Board
• Sven Wehrwein,
  Independent Director
• Mark Lanning,
  Independent Director
• B. Kristine Johnson,
  Independent Director
• Robert White,
  Independent Director
• Regina Groves,
  Independent Director
• Mark Collar,
  Independent Director
• Karen Prange,
  Independent Director
• Daniel Florin,
  Independent Director
• Angela Wirick,
  Chief Financial Officer
• Shlomo Nachman,
  Director
• Karen P Robards,
  Director
• Elizabeth D Krell,
  Director
• Richard M Johnston,
  Director
• Michael D Hooven,
  Director
• Andrew L Lux,
  V.P. & Chief Operating Officer
• Group I, Llc Murphy Michael...,
  
• M. Andrew Wade,
  CFO
• Tonya Austin,
  Chief Human Resources Officer
• Deborah L Morley,
  VP Clinical Affairs
• Lee R Wrubel,
  Director
• Maureen Shaffer,
  Vice President Marketing
• Jon A Sherman,
  VP Product Development
• Elsa Chi Abruzzo,
  VP; Regulatory&ClinicalAffairs
• Alan L Kaganov,
  Director
• Richard S Walsh,
  Vice President; Sales
• Management Group Viii L L C...,
  
• Management Group Viii L L C...,
  
• Stephen S Cambridge,
  Vice President; Sales
• Management Group Viii L L C...,
  
• Thomas J Etergino,
  Vice President and CFO
• Norman R Weldon,
  Director
• Patricia J Kennedy,
  VP, GM, International
• James L Lucky,
  VP; QA & Healthcare Compliance
• Management Group Viii L L C...,
  
• David J Drachman,
  President and CEO
• Richard Mcamden Partners St...,
  
• Richard Mcamden Partners St...,
  
• Donald C Harrison,
  Director
• Group I, Llc Donoghue Danie...,
  
• Stewart W Strong,
  Vice President US Sales
• Management Group Viii L L C...,
  
• Frederick Preiss,
  Vice President; Operations
• Julie A Piton,
  VP and CFO
• Deborah H Telman,
  Director
• Karl S. Dahlquist,
  Chief Legal Officer
• Vinayak Doraiswamy,
  Chief Scientific Officer
• Maggie Yuen,
  Director
• Deborah Lee Yount,
  Chief Human Resources Officer